Skip to main content

Table 3 Crude and adjusted rate ratios of pneumonia associated with current use of the different dopamine agonists relative to non-current use

From: Pramipexole use and the risk of pneumonia

 

Cases

Controls

Crude

Adjusted*

Rate Ratio

Rate ratio

95% CI

Number of subjects

1835

16088

   

Current use† of:

     

 Any dopamine agonist (%)

269 (14.7)

2,846 (17.7)

0.77

0.87

0.75 – 1.02

  Pramipexole (%)

59 (3.2)

734 (4.6)

0.64

0.76

0.57 – 1.02

  Ropinirole (%)

92 (5.0)

1,095 (6.8)

0.69

0.76

0.60 – 0.97

  Cabergoline (%)

57 (3.1)

397 (2.5)

1.15

1.28

0.94 – 1.75

  Pergolide (%)

43 (2.3)

418 (2.6)

0.90

1.06

0.76 – 1.50

  Other dopamine agonists‡ (%)

23 (1.3)

234 (1.5)

0.74

0.77

0.48 – 1.22

  1. * Adjusted for one another, for current use of other anti-Parkinsonian drugs, including levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all factors listed in Table 1.
  2. † Current use refers to a prescription ending after or within 30 days prior to the index date.
  3. ‡ Regroups rotigotine, bromocriptine, and lisuride because of low frequencies.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us